Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2016

View Archived Issues

Bristol-Myers Squibb presents novel PAR-4 antagonists as promising antithrombotic agents

Cynata and FUJIFILM reach agreement to develop and commercialize regenerative medicine products

Cyr61 identified as a novel biomarker of coronary events

HP-3070 enters phase III clinical testing in the U.S. in patients with schizophrenia

Exeporfinium chloride demonstrates safety, tolerability and efficacy in U.S. clinical trial

OGD2 Pharma collaborates with Syndivia to develop ADCs targeting OAcGD2 antigen

FDA accepts for review CCP-07 NDA

TRx-237-007 phase III trial fails to achieve its coprimary endpoints

Cardiosphere-derived cell therapy shows benefit in single ventricle heart failure patients

Horizon Discovery collaborates with Fulcrum Therapeutics on CRISPR-based target discovery

Ciprofloxacin DPI shows efficacy in NCFB: first data from the RESPIRE 1 trial

New phase I trial tests Viaskin rPT to reactivate pertussis toxin immunity

European orphan drug designation for GLPG-1690 in IPF

Fresenius Helios to acquire Quironsalud

Biomarkers linked to excess reactive oxygen species identified in non-Hodgkin's lymphoma

Bayer in advanced negotiations with Monsanto

Latvian Institute of Organic Synthesis patents LeuRS inhibitors

NEONC Technologies patent reports agents for treatment of cancer

Lilly prepares and tests MetAP 2 and DPP IV inhibitors

Agents for RSV infections described in Aviragen Therapeutics patent

PCI Biotech updates progress of phase I/II bile duct cancer study

University of Southern California team reveals growth hormone receptor antagonists

131-I-8H9 monoclonal antibody granted FDA orphan drug designation in neuroblastoma

AbbVie's venetoclax granted new FDA orphan drug designation

FDA gives dabrafenib and trametinib orphan drug designation in thyroid cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...